Evidence map›Paper›PMID 39157684›Full record

ArticleVaccine: X2024

Effects of different HA and NA gene combinations on the growth characteristics of the H3N8 influenza candidate vaccine virus.

Liqi Liu, Zi Li, Jia Liu, Xiyan Li, Jianfang Zhou, Ning Xiao, Lei Yang, Dayan Wang

Abstract read
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liqi LiuNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Zi LiNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Jia LiuNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Xiyan LiNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Jianfang ZhouNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Ning XiaoNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Lei YangNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.
Dayan WangNational Institute for Viral Disease Control and Prevention, China CDC, Beijng, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 2022, three human cases of a novel H3N8 avian influenza virus infection have been reported in three provinces in China. Specific vaccines are important means of preparing for the potential influenza pandemic. Thus, H3N8 viruses [A/Henan/cnic410/2022 (HN410) and A/Changsha/1000/2022(CS1000)] were isolated from the infected patients as prototype viruses to develop candidate vaccine viruses (CVVs) using the reverse genetics (RG) technology. Five reassortant viruses with different HA and NA combinations were constructed based on the two viruses to get a high-yield and safe CVV. The results showed that all viruses had similar antigenicity but different growth characteristics. Reassortant viruses carrying NA from CS1000 exhibited better growth ability and NA enzyme activity than the ones carrying HN410 NA. Furthermore, the NA gene of CS1000 had one more potential N-glycosylation site at position 46 compared with HN410. The substitution of position 46 showed that adding or removing N-glycosylation sites to different reassortant viruses had different effects on growth ability. A reassortant virus carrying HN410 HA and CS1000 NA with high growth ability was selected as a CVV, which met the requirements for a CVV. These data suggest that different surface gene combinations and the presence or absence of potential N-glycosylation sites on position 46 in the NA gene affect the growth characteristics of H3N8 CVVs.

Indexed as

Candidate vaccine virusGrowth characteristicsH3N8 avian influenza virusNA enzyme activityN-glycosylation site

Identifiers

PMID39157684
PMCPMC11326938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.